Subscribe to Money Morning get daily headlines subscribe now! Money Morning Private Briefing today's private briefing Access Your Profit Alerts

Immunogen Inc (NASDAQ: IMGN)

$4.72 USD -$0.35 (-6.90%)
Last Price $4.72
Net Change $-0.35 (-6.9%)
Bid $0
Ask Price $0
Open Price $5.05
Previous Close Price $5.07
High Price $5.05
Low Price $4.55
Number of Trades 7,787
Volume 2,413,200
Fifty Two Week High $6.21 (2016-06-03)
Fifty Two Week Low $1.51 (2016-11-03)
Average Daily Volume 2,186,266
Share Outstanding 89,350 Shares
Total Dividend Payout 0/yr
Dividend Yield 0%
1st Quarter Earnings $-0.2 (2017-05-05)
2nd Quarter Earnings $-0.39 (2017-02-17)
3nd Quarter Earnings $-0.51 (2016-08-04)
4th Quarter Earnings $-0.37 (2016-04-29)
PE Ratio $0
EPS Growth $13.03
Recent Earnings $-0.2
Annual EPS $-1.56
Last Quarter EPS $
Market Capitalization $0.42B
Insider Shareholders % 0.05%
Annual Revenue $0B
No. Shares Outstanding 89,350
Inst. Shareholder % 73.94%
Annual Net Income $-0.14B
TTM Net Profit Margin $-245.54
1-Year Return -16.61%
3-Year Return -59.52%
5-Year Return -67.38%
5-Year Revenue Growth 266.75%
5-Year Earnings Growth 94.12%
5-Year Dividend Growth 0%
Annual Dividend $0
Annual Dividend Yield 0%
Change in EPS YTD 13.03%
Dividends per Share $
Stock Split Ratio
Beta 2.19
ImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The company's product candidates are called tumor-activated prodrugs and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, tumor-activated prodrugs are intended to deliver potent chemotherapy specifically to a tumor. Each tumor-activated drug immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody.

IMGN News & Stock Updates